Bionova Scientific, Inc.

Founded in 2014 and acquired by the Asahi Kasei Group in 2022, Bionova Scientific offers world-class biologics CDMO services built on a foundation of strong process development and analytical science with a staff that brings decades of experience in late stage and commercial launch projects. With its high quality, customized biomanufacturing services, cutting-edge process development expertise and data-driven risk minimization strategies, the company is renowned for helping client projects move quickly from concept to robust GMP production. Bionova Scientific’s operations are optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins.